Wednesday, February 14, 2024

Latigo Biotherapeutics Finds $135M

Thousand Oaks-based Latigo Biotherapeutics, a biotherapeutics company developing non-opioid pain medications, says it has raised $135M in a Series A funding round. The funding was led by Westlake Village BioPartners, which originally incubated the company. Additional Series A financing came from 5AM Ventures and Foresite Capital as co-leads, plus Corner Ventures. As part of the investment, the company said it has named Desmond Padhi, PharmD,as interim CEO, and Nancy Stagliano, Ph.D., CEO of Neuron23, as Chair of the board.